Actinium Pharmaceuticals, Inc. (ATNM) Stock Forecast
ATNM analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.20 / 5 from 5 analysts
- Price target
- $3.60 average of analyst targets
- Upside to target
- +218.6% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.25
- 52-week range
- $0.75 – $1.69
ATNM analyst ratings
5 analystsNumber of analysts at each rating.
ATNM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ATNM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.27 | −$0.24 | −$0.16 | −59.4% | 2 |
| Current fiscal year (2026) | $0.14 | $0.12 | $0.16 | −$1.09 | +112.8% | 2 |
| Next fiscal year (2027) | −$0.53 | −$0.72 | −$0.33 | $0.14 | −475.0% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ATNM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 4 |
| Current fiscal year (2026) | $17.5M | $0 | $35.0M | +19,344.4% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 4 |
ATNM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ATNM revenue: reported and forecast
ATNM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.24 | −$0.24 | −$0.24 | −$0.26 | +8.5% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.84 | −$0.91 | −$0.91 | −$0.91 | $0.14 | −116.7% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.48 | −$0.35 | −$0.35 | −$0.35 | −$0.53 | +10.1% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ATNM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ATNM beat in 10 of 12.
What analysts expect from ATNM
5 analysts cover Actinium Pharmaceuticals; their consensus rating is buy (4.20 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.60, 218.6% above the latest close of $1.13. Analysts expect earnings of $0.14 per share for 2026, +112.8% from a year earlier. For 2027 the average estimate is −$0.53 per share. Actinium Pharmaceuticals beat the EPS estimate in 10 of the last 12 quarters.
Related: ATNM income statement, ATNM key metrics, ATNM chart. See the ATNM stock overview for the latest quote and news.
ATNM forecast FAQ
What is Actinium Pharmaceuticals's price target?
The average analyst price target for Actinium Pharmaceuticals is $3.60, 218.6% above the latest close of $1.13.
Is Actinium Pharmaceuticals a buy, hold or sell?
Of 5 analysts covering Actinium Pharmaceuticals, 2 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Actinium Pharmaceuticals's EPS forecast?
Analysts forecast $0.14 per share for 2026 (range $0.12 to $0.16); for 2027 the estimate is −$0.53.
What is Actinium Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $17.5 million, growth of 19,344.4%.
When does Actinium Pharmaceuticals report earnings?
Actinium Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.25.
Does Actinium Pharmaceuticals usually beat earnings estimates?
Actinium Pharmaceuticals reported EPS at or above the analyst estimate in 10 of the last 12 quarters.